在沙特阿拉伯,药剂师自我报告的对提供抗凝剂药品护理的信心
Ghada Alem1, Nehad Jaser Ahmed1, Noura Albarak2
1Department of Clinical Pharmacy, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al Kharj, Saudi Arabia.
Journal of public health research
|December 22, 2025
概括
沙特阿拉伯的药剂师对抗凝血剂的管理表现出适度的信心,在处理出血事件方面存在明显的差距. 进一步培训应侧重于高风险场景的实际技能.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 医疗保健 专业教育 医疗保健 专业教育
背景情况:
- 抗凝剂治疗是一种高风险的治疗方法,需要专门的药剂师能力.
- 沙特阿拉伯的药剂师对抗凝血剂管理的信心水平并不成熟.
- 这项研究解决了评估沙特阿拉伯药剂师对抗凝血剂患者药物护理的信心的需要.
研究的目的:
- 评估沙特阿拉伯药剂师自我报告的信心水平.
- 评估为接受抗凝剂治疗的患者提供药物护理的信心.
- 确定药剂师对抗凝血药物管理的信心的优点和弱点.
主要方法:
- 在沙特阿拉伯的药剂师中进行了一项横截面的在线调查.
- 该调查评估了跨领域的信心,包括知识,不良事件管理和患者咨询.
- 描述性统计,t测试和后勤回归被用于数据分析.
主要成果:
- 在194名受访者中,自我报告的信心总体上是适度的 (70.3%).
- 药剂师对基本任务 (例如,指示,不良反应) 充满信心,但对管理诸如出血事件 (~60%) 等关键场景的信心较低.
- 医院药剂师报告的信心高于社区药剂师;莱克西康普和临床指南是主要资源.
结论:
- 沙特药剂师拥有基础知识,但在管理严重抗凝药并发症方面表现出显著的信心差距.
- 继续教育应强调实践,基于案例的培训,特别是血液管理和应急响应.
- 该研究依赖于自我报告的数据是一个局限性,可能不反映客观能力.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Pharmacodynamics in Geriatric Patients: Effects of Age
174
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
174
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
209
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
209
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
234
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
234


